European Respiratory Review
Volume 18, Issue 112, June 2009
- « Previous Issue
- All Issues
- Next Issue »
- In this publication
-
Biologics in severe difficult-to-treat asthma: find the right niche!
More details- pp. 51–53
Author: M. Humbert
- DOI: 10.1183/09059180.00001509
-
Activity limitation: a major consequence of dyspnoea in COPD
More details- pp. 54–57
Author: N. Roche
- DOI: 10.1183/09059180.00001309
-
Update on severe asthma: what we know and what we need
More details -
A physiological model of patient-reported breathlessness during daily activities in COPD
More details- pp. 66–79
Authors: C. J. Jolley; J. Moxham
- DOI: 10.1183/09059180.00000809
Breathlessness during daily activities has a significant impact on quality of life in chronic obstructive pulmonary disease. Herein, we present a physiological model of patient-reported breathlessness based on the relationship between ventilatory load, respiratory muscle capacity, neural respiratory drive and neuromechanical dissociation during daily activities. This model should facilitate an understanding of the mechanisms driving increased intensity of breathlessness during daily activities and the relief of breathlessness following medical or surgical interventions.
The model should also provide a structure on which to base the development of patient-reported outcome instruments to measure the severity of breathlessness during daily activities in chronic obstructive pulmonary disease.
-
Update on the roles of distal airways in asthma
More details- pp. 80–95
Authors: P-R. Burgel; J. de Blic; P. Chanez; C. Delacourt; P. Devillier; A. Didier; J-C. Dubus; I. Frachon; G. Garcia; M. Humbert; F. Laurent; R. Louis; A. Magnan; B. Mahut; T. Perez; N. Roche; I. Tillie-Leblond; M. Tunon de Lara; D. Dusser
- DOI: 10.1183/09059180.00001109
The present review is the summary of an expert workshop that took place in Vence (France) in 2007 on the role of distal airways in asthma. The evidence showing inflammation and remodelling in distal airways, and their possible involvement in asthma control and natural history, was reviewed. The usefulness and limitations of various techniques used for assessing distal airways were also evaluated, including pulmonary function tests and imaging. Finally, the available data studying the benefit of treatment better targeting distal airways in asthma was examined. It was concluded that both proximal and distal airways were involved in asthma and that distal airways were the major determinant of airflow obstruction. Inflammation in distal airways appeared more intense in severe and uncontrolled asthma. Distal airways were poorly attained by conventional aerosol of asthma medications owing to their granulometry, being composed of 3–5 μm particles. Both proximal and distal airways might be targeted either by delivering medications systemically or by aerosol of extra-fine particles. Extra-fine aerosols of long-acting β-agonists, inhaled corticosteroids or inhaled corticosteroid/long-acting β-agonist combinations have been shown in short-term studies to be not inferior to non-extra-fine aerosols of comparators. However, available studies have not yet demonstrated that extra-fine inhaled medications offer increased benefit compared with usual aerosols in asthmatic patients.
-
Biomarkers in the management of COPD
More details- pp. 96–104
Authors: A. Lacoma; C. Prat; F. Andreo; J. Domínguez
- DOI: 10.1183/09059180.00000609
Chronic obstructive pulmonary disease (COPD) is still a leading cause of morbidity and mortality worldwide, with a huge socioeconomic impact. New strategies for the management of COPD are required, not only for identifying the origin of the exacerbation episodes, but also to assess an individual risk for each patient. A promising approach is to measure systemic biomarkers and correlate their levels with exacerbation characteristics and clinical prognosis of the disease. Several biomarkers have clearly correlated with the aetiology of lower respiratory tract infections and the response to antibiotic treatment, indicating a potential utility in COPD exacerbation. Nevertheless, the results available at the moment, together with the absence of a gold standard for identifying the aetiological origin of an exacerbation, impedes establishing the real utility of these biomarkers for this concrete task. Regarding the clinical evolution and prognosis, several clinical characteristics have been correlated to biomarker levels. The potential influence of many factors (severity of the disease, presence of comorbidities and treatment) leads to the conclusion that, in the future, the best option would be to monitor levels individually, rather than establishing cut-off points for the general COPD population.
-
Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK
More details- pp. 105–112
Authors: P. Demoly; P. Paggiaro; V. Plaza; S. C. Bolge; H. Kannan; B. Sohier; L. Adamek
- DOI: 10.1183/09059180.00001209
The objectives of this article were to estimate the prevalence of asthma control and describe the characteristics of at least well-controlled (ALWC)
versus not well-controlled (NWC) asthmatics.Data were obtained from the European National Health and Wellness Survey, an internet-based, cross-sectional study of 37,476 adults in France, Germany, Italy, Spain and the UK. Analysis was limited to 2,337 respondents who self-reported a physician diagnosis. Based on the Asthma Control Test (ACT), respondents were grouped as ALWC (ACT ≥20) and NWC (ACT ≤19).
The prevalence of diagnosed asthma across five countries was estimated to be 5.8% (14 million extrapolated for the European Union population). Of these, 50.4% (7.1 million) were NWC. Compared with ALWC, NWC were older (15.8
versus 15.0%; p<0.001), less likely to be college educated (28.7versus 36.3%; p<0.001) and more likely to be obese (30.0versus 22.7%; p<0.001), experience depression (28.0versus 18.7%; p<0.001) and smoke (34.7versus 25.0%; p<0.001). The NWC had more occasions of contact with healthcare providers and were more likely to use controller and rescue medications, but with less adherence.A substantial portion of asthmatics are NWC. However, the proportion of NWC asthmatics found in this study was less than in previously reported. Patients and physicians need to be educated on the importance of asthma control and adherence to treatments.
-
Metabolic aspects of obstructive sleep apnoea syndrome
More details- pp. 113–124
Authors: M. R. Bonsignore; J. Eckel
- DOI: 10.1183/09059180.00000109
Insulin resistance is often associated with obstructive sleep apnoea syndrome (OSAS) and could contribute to cardiovascular risk in OSAS. Sleep loss and intermittent hypoxia could contribute to the pathogenesis of the metabolic alterations associated with obesity, a common feature of OSAS. The biology of the adipocyte is being increasingly studied, and it has been found that hypoxia negatively affects adipocyte function.
In November 2007, the European Respiratory Society and two EU COST Actions (Cardiovascular risk in OSAS (B26) and Adipose tissue and the metabolic syndrome (BM0602)), held a Research Seminar in Düsseldorf, Germany, to discuss the following: 1) the effects of hypoxia on glucose metabolism and adipocyte function; 2) the role of inflammatory activation in OSAS and obesity; 3) the alarming rates of obesity and OSAS in children; 4) the harmful effects of the metabolic syndrome in OSAS; 5) the effects of OSAS treatment on metabolic variables; and 6) the relationship between daytime sleepiness and hormonal and inflammatory responses. Insulin resistance in skeletal muscle, the role of the endocannabinoid system and novel pharmacological approaches to treat insulin resistance were also discussed.
As obesity and hypoxia could be the basic links between OSAS and adipocyte dysfunction, further research is needed to translate these new data into clinical practice.
-
Pulmonary arterial hypertension in a patient with stage II sarcoidosis and Hashitoxicosis
More details- pp. 125–128
Authors: S. Ocak; F. Feoli; J. Fastrez; D. Butenda; C. Litvine; I. M. Colin; J-P d'Odémont
- DOI: 10.1183/09031936.00000309
Although pulmonary arterial hypertension is usually associated with advanced stages of sarcoidosis, its occurrence in early stage disease is rare. Herein, a case of associated pulmonary arterial hypertension in the setting of Hashitoxicosis and stage II pulmonary sarcoidosis is reported. The case of associated pulmonary arterial hypertension occurred in a young female without clinically significant medical history and who completely recovered after receiving oral corticotherapy only. Furthermore, this case report suggests the presence of an interaction between pulmonary arterial hypertension, sarcoidosis and Hashitoxicosis.
-
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
More details- pp. 129–132
Authors: K. Sakamoto; H. Taniguchi; Y. Kondoh; K. Ono; Y. Hasegawa; M. Kitaichi
- DOI: 10.1183/09059180.00000409
The clinical course of patients with idiopathic pulmonary fibrosis (IPF) is generally marked by a decline in pulmonary function over time, although recently there is increasing recognition that fatal deterioration from acute exacerbation can occur at any stage.
The patient described in the present case study was a 65-yr-old male who presented with exertional dyspnoea and fever of 2 weeks' duration. He had no history of chronic lung disease or physiological or radiological hallmarks of pre-existing disease. He underwent surgical lung biopsy and the histological examination showed a background pattern of usual interstitial pneumonia (UIP) with a pattern of focal acute diffuse alveolar damage (DAD) in the area where normal lung architecture was preserved.
It is notable that the pathological diagnosis of this rapidly progressive interstitial pneumonia was DAD on UIP, which is typically seen in acute exacerbations of IPF. Unusual findings on high-resolution computed tomography scan were also noted.
We presume that in this case acute exacerbation developed in the very early course of IPF. Given the possibility that similar cases may have arisen among patients diagnosed with acute interstitial pneumonia or acute respiratory distress syndrome, the histopathology of rapidly progressive interstitial pneumonia may need to be revisited.
-
Chronic Obstructive Pulmonary Disease (COPD)
More details- pp. 133–133
Author: E. Weitzenblum


